Obezita blocks some of the fat that you eat, keeping it from being absorbed by your body.
Obezita is used together with a reduced-calorie diet and weight maintenance to treat obesity in people with certain risk factors (such as diabetes, high blood pressure, and high cholesterol or triglycerides).
Obezita may also be used for purposes not listed in this medication guide.
It is dangerous to purchase Obezita on the Internet or from vendors outside of the United States. Medications distributed from Internet sales may contain dangerous ingredients, or may not be distributed by a licensed pharmacy. Samples of "Obezita" purchased on the Internet have been found to contain sibutramine (Meridia), a prescription weight loss medication that can have dangerous side effects in certain people. For more information, contact the U.S. Food and Drug Administration (FDA) or visit www.fda.gov/buyonlineguide.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
Obezita™ (Obezita 60 mg) is indicated for weight loss in overweight adults, 18 years and older, when used along with a reduced-calorie and low-fat diet.
Diet and exercise are the starting points for any weight loss program. Try these first before adding Obezita (Obezita 60 mg). Check with your doctor before starting any exercise program.
To determine if Obezita (Obezita 60 mg) capsules are right for you, find your height on the chart below. You may consider starting with Obezita (Obezita 60 mg) if your weight is the same or more than the weight shown for your height.
How should I use Obezita?
Use Obezita as directed by your doctor. Check the label on the medicine for exact dosing instructions.
An extra patient leaflet is available with Obezita. Talk to your pharmacist if you have questions about this information.
Read the chart on the medicine package. You may consider starting Obezita if your weight is the same or more than the weight shown for your height. Talk to your doctor or pharmacist if you have any questions.
Take Obezita by mouth with each meal. Do not take more than 3 capsules daily.
If a meal is missed or contains no fat, do not take a dose of Obezita.
Obezita may decrease your absorption of vitamins. Take a multivitamin once a day at bedtime.
If you also take a thyroid hormone (eg, levothyroxine), do not take it within 4 hours before or after taking Obezita. Check with your doctor if you have questions.
If you also take cyclosporine, do not take it within 3 hours before or after taking Obezita. Check with your doctor if you have questions.
If you miss a dose of Obezita, skip the missed dose. Continue to take it as directed by your doctor or on the package label.
Ask your health care provider any questions you may have about how to use Obezita.
Uses of Obezita in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
Use: Labeled Indications
OTC: Weight loss in overweight adults when used along with a reduced-calorie and low-fat diet.
Rx: Obesity management, including weight loss and weight maintenance, when used in conjunction with a reduced-calorie diet; to reduce the risk for weight regain after prior weight loss.
Limitations of use: Obezita is indicated for obese patients with an initial body mass index of ≥30 kg/m in the presence of other risk factors (eg, hypertension, diabetes, dyslipidemia).
Obezita is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. Obezita works by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested.
The recommended dose of Obezita is one 120-mg capsule three times a day with each main meal containing fat (during or up to 1 hour after the meal).
The patient should be on a nutritionally balanced, reduced-calorie diet that contains approximately 30% of calories from fat. The daily intake of fat, carbohydrate, and protein should be distributed over three main meals. If a meal is occasionally missed or contains no fat, the dose of Obezita can be omitted.
Because Obezita has been shown to reduce the absorption of some fat-soluble vitamins and betacarotene, patients should be counseled to take a multivitamin containing fat-soluble vitamins to ensure adequate nutrition. The vitamin supplement should be taken at least 2 hours before or after the administration of Obezita, such as at bedtime.
For patients receiving both Obezita and cyclosporine therapy, administer cyclosporine 3 hours after Obezita.
For patients receiving both Obezita and levothyroxine therapy, administer levothyroxine and Obezita at least 4 hours apart. Patients treated concomitantly with Obezita and levothyroxine should be monitored for changes in thyroid function.
Doses above 120 mg three times a day have not been shown to provide additional benefit.
Based on fecal fat measurements, the effect of Obezita is seen as soon as 24 to 48 hours after dosing. Upon discontinuation of therapy, fecal fat content usually returns to pretreatment levels within 48 to 72 hours.
Dosage Forms And Strengths
Obezita 120 mg turquoise capsules imprinted with ROCHE and Obezita 120 in black ink.
Obezita is a turquoise, hard-gelatin capsule containing pellets of powder.
Obezita 120 mg Capsules: Turquoise, two-piece, No. 1 opaque hard-gelatin capsule imprinted with ROCHE and Obezita 120 in black ink - bottle of 90 (NDC 0004-0257-52).
Storage And Handling
Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). Keep bottle tightly closed.
Obezita should not be used after the given expiration date.
Distributed by: Genentech USA, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990. Revised: Aug 2016
Amiodarone: Obezita may decrease the serum concentration of Amiodarone. Monitor therapy
Anticonvulsants: Obezita may decrease the serum concentration of Anticonvulsants. Exceptions: Fosphenytoin; PENTobarbital; Thiopental. Monitor therapy
Antiretroviral Agents: Obezita may decrease the serum concentration of Antiretroviral Agents. Monitor therapy
CycloSPORINE (Systemic): Obezita may decrease the serum concentration of CycloSPORINE (Systemic). Management: Administer Obezita at least 3 hours before or after oral cyclosporine. Monitor for decreased serum concentrations of oral cyclosporine, even with the recommended dose separation. Consider therapy modification
Levothyroxine: Obezita may decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and Obezita by a least 4 hours. Monitor patients closely for signs and symptoms of hypothyroidism. Consider therapy modification
Multivitamins/Fluoride (with ADE): Obezita may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, Obezita may impair absorption of fat-solube vitamins. Management: Administer oral fat soluble vitamins (such as vitamins A, D, E, and/or K that are contained in many multivitamin products) at least 2 hours before or after the administration of Obezita. Consider therapy modification
Multivitamins/Minerals (with ADEK, Folate, Iron): Obezita may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, Obezita may impair the absorption of fat-soluble vitamins. Management: Administer oral fat soluble vitamins (such as vitamins A, D, E, and/or K that are contained in many multivitamin products) at least 2 hours before or after the administration of Obezita. Consider therapy modification
Multivitamins/Minerals (with AE, No Iron): Obezita may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, Obezita may impair absorption of fat-solube vitamins. Management: Administer oral fat soluble vitamins (such as vitamins A, D, E, and/or K that are contained in many multivitamin products) at least 2 hours before or after the administration of Obezita. Consider therapy modification
Paricalcitol: Obezita may decrease the serum concentration of Paricalcitol. Management: Monitor clinical response to paricalcitol closely when used with Obezita. When this combination must be used, consider administering paricalcitol at least 1 hour before or 4 to 6 hours after the administration of Obezita Consider therapy modification
Propafenone: Obezita may decrease the serum concentration of Propafenone. Monitor therapy
Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Consider therapy modification
Vitamin D Analogs: Obezita may decrease the serum concentration of Vitamin D Analogs. More specifically, Obezita may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with Obezita. If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after Obezita. Exceptions: Calcipotriene; Calcitriol (Topical); Tacalcitol. Consider therapy modification
Vitamin K Antagonists (eg, warfarin): Obezita may enhance the anticoagulant effect of Vitamin K Antagonists. Monitor therapy
Vitamins (Fat Soluble): Obezita may decrease the serum concentration of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or after the administration of Obezita. Similar precautions do not apply to parenterally administered fat soluble vitamins. Exceptions: Calcipotriene. Consider therapy modification
Some people on Obezita™ (Obezita 60 mg) will experience GI side effects, which is expected since Obezita (Obezita 60 mg) works by inhibiting about 25% of dietary fat. Obezita (Obezita 60 mg) is half the strength of prescription Obezita® (Obezita 120 mg), and, as a result, has fewer GI events overall than Obezita®. In clinical trials, subjects on 120 mg withdrew due to GI adverse events at a rate of 5.4%-and at 60 mg it was only 3.2%.
The main treatment effect occurs when an individual eats a meal with too much fat while taking Obezita (Obezita 60 mg). Treatment effects may include:
Loose or more frequent stools that may be hard to control
An urgent need to go to the bathroom
Gas with oily spotting
While excess fat that is excreted is not harmful, patients could be distressed by the experience. Treatment effects can be lessened if an individual sticks with reduced-calorie, low-fat meals that average 15 grams of fat per meal (or 30% fat or less). Diets may vary from 1,200 calories to 1,800 calories per day, so 15 grams is an average. Individuals need to be aware of hidden fat in food, so that they can lower the chance of having treatment effects.
Not all individuals will experience treatment effects, but those that do can reduce the likelihood of these effects by taking Obezita (Obezita 60 mg) as directed and sticking with a reduced-calorie, low-fat diet. The Obezita (Obezita 60 mg) starter pack includes portable reference guides and online support at myalli (Obezita 60 mg).com to help patients follow the program accurately. Some patients may experience treatment effects as they begin therapy until they learn to adjust their diet.
Do not take Obezita if you are pregnant. Weight loss is not recommended during pregnancy, even if you are overweight or obese.
You should not take this medication if you are allergic to Obezita, if you are pregnant, or if you have gallbladder problems or chronic malabsorption syndrome (an inability to absorb food and nutrients properly).
Before taking Obezita, tell your doctor if you have an underactive thyroid, a history of gallstones or pancreatitis, type 1 or type 2 diabetes, an eating disorder, liver or kidney disease, or if you take other weight-loss medications (prescription or over-the-counter).
Do not give over-the-counter Obezita to a child younger than 18 years old. Prescription Obezita should not be used by anyone age 12 to 18 without the advice of a doctor.
Obezita should be used only by the person for whom it was prescribed. Never share Obezita with another person, especially someone who has a history of eating disorder. Keep the medication in a place where others cannot get to it.
Obezita is only part of a complete program of treatment that also includes diet, exercise, and weight control. Your daily intake of fat, protein, and carbohydrates should be evenly divided over all of your daily meals. Follow your diet, medication, and exercise routines very closely.
Avoid a diet that is high in fat. High-fat meals taken in combination with Obezita can increase your risk of unpleasant side effects on your stomach or intestines.
DailyMed. "ORLISTAT: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Obezita are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Obezita. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
5 consumers reported time for results
To what extent do I have to use Obezita before I begin to see changes in my health conditions? As part of the reports released by ndrugs.com website users, it takes 1 month and a few days before you notice an improvement in your health conditions. Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Obezita. To get the time effectiveness of using Obezita drug by other patients, please click here.
> 3 month
8 consumers reported age
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology